Therapeutic Hydrocortisone Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome +18 more

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

OHSU Knight Cancer Institute1
National Cancer Institute (NCI)1
Children's Oncology Group1

Indications

Cancer3
B Acute Lymphoblastic Leukemia1
Acute Leukemia of Ambiguous Lineage1
Hematopoietic and Lymphatic System Neoplasm1
Acute Myeloid Leukemia1

Birmingham, Alabama2 trials

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Hospital of Alabama

Phase 3

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Portland, Oregon1 trial

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

OHSU Knight Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.